ABBOTT LABORATORIES (ABT) Options Risk Score
Real-time risk analysis for ABT options traders — updated every 30 minutes.
Data last updated: 2026-07-23
Run a full ABT options risk analysis
See the complete risk breakdown — news catalysts, SEC filings, legal proceedings, earnings overlap, IV vs HV, options flow and Expected Move — all in one scan.
Scan ABT Now — Free →
Is it risky to sell options on ABBOTT LABORATORIES (ABT) right now?
ABBOTT LABORATORIES (ABT) currently scores 69 out of 100 for options catalyst risk (MEDIUM) over a 4-week expiry window. What pushes it there: an upcoming earnings report, 12 recent news items, 10 active legal filings and 36 clinical-trial catalysts, all landing inside the 4-week window. MEDIUM covers 45 to 69: there is something on ABT's calendar worth reading before you pick an expiry, without it dominating the trade. Direction is not part of what the score measures.
ABT shows an IV Rank of 61, putting implied volatility in the middle of its one-year range — options are moderately priced, with a current implied volatility of about 33%. Read IV Rank alongside the catalyst score: it says how expensive ABT options are, while the score says whether that price is justified by a scheduled event.
ABT reports on 2026-10-14. Any expiry beyond that date carries the gap, and the implied volatility priced in beforehand typically collapses the morning after.
TickerRisk provides risk scoring for informational purposes only. This is not financial advice. Options trading involves substantial risk of loss. Full disclaimer